Neutralizing antibodies (nAbs), the popular antiviral drugs used for the treatment of COVID-19, are effective in reducing viral load and hospitalization. Currently, most nAbs are screened from convalescent or vaccinated individuals through single B-cell sequencing which requires cutting-edge facilities. Moreover, owing to the rapid mutation of SARS-CoV-2, some approved nAbs are no longer effective. In the present study, we designed a new approach to acquiring broadly neutralizing antibodies (bnAbs) from mRNA-vaccinated mice. Using the flexibility and speed of mRNA vaccine preparation, we designed a chimeric mRNA vaccine and sequential immunization strategies to acquire bnAbs in mice within a short period. By comparing different vaccination orders, we found that the initially administered vaccine had a greater effect on the neutralizing potency of mouse sera. Ultimately, we screened a strain of bnAb that neutralized wild-type, Beta, and Delta SARS-CoV-2 pseudoviruses. We synthesized the mRNAs of the heavy and light chains of this antibody and verified its neutralizing potency. This study developed a new strategy to screen for bnAbs in mRNA-vaccinated mice and identified a more effective immunization strategy for inducing bnAbs, providing valuable insights for future antibody drug development.
Background: Cisplatin chemotherapy is limited by its nephrotoxicity, which leads to acute kidney injury (AKI). Ferroptosis is a key pathogenic mechanism in cisplatin-induced AKI. Formononetin (FN), a natural isoflavone, has demonstrated antioxidant and renoprotective potential, but its role in modulating ferroptosis remains unclear. Methods: A cisplatin-induced AKI model in mice and a cisplatin-injured HK-2 cell model were established. Kidney injury was assessed via serum creatinine, blood urea nitrogen, H&E staining, and Kim-1 expression. Ferroptosis was evaluated by measuring glutathione (GSH), malondialdehyde (MDA), iron deposition, lipid peroxidation, mitochondrial morphology, and the expression levels of GPX4, SLC7A11, FTH and FTL. The involvement of the NRF2 pathway was investigated using the inhibitor ML385 in vivo and siRNA in vitro . The role of the PI3K/AKT pathway was assessed using the inhibitor LY294002. Results: FN treatment significantly improved renal function and attenuated tubular damage in cisplatin-induced AKI. It suppressed key features of ferroptosis, as shown by increased GSH, decreased MDA and iron levels, and preserved mitochondrial integrity. FN also reduced the oxidized lipids, and reversed the cisplatin-induced downregulation of SLC7A11 and GPX4. The renoprotective and anti-ferroptotic effects of FN were abolished by the NRF2 inhibitor ML385 in vivo and by siRNA in vitro . Furthermore, FN activated the PI3K/AKT pathway, and the PI3K inhibitor LY294002 blocked FN-mediated upregulation of NRF2 and GPX4. Conclusion: FN protects against cisplatin-induced AKI by inhibiting ferroptosis. This effect is mechanistically associated with the activation of the PI3K/AKT pathway, which subsequently enhances NRF2 signaling and upregulates GPX4 expression. Our findings support FN as a potential candidate for further investigation in the prevention of cisplatin nephrotoxicity.